NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p<0.0001), which was sustained at day 365 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at day 84 and 41.5% at day 365, compared to placebo -- -- Observed to be generally well-tolerated with safety results comparable to placebo -- -- NewAmsterdam to host conference call at 8:30 a.m. ET, Today -- NAARDEN, the Netherlands and MIAMI, July 2 ...